NASDAQ · Biotechnology

Adaptive Biotechnologies Corporation (ADPT) Stock

$26.49 +1.53% NASDAQ: ADPT Healthcare

Valuation

MetricValue
Price$26.49
Market Cap$4.24B
P/E Ratio-71.77
P/B Ratio32.27
P/S Ratio15.19
EPS (TTM)$-0.39
52-Week High$30.30
52-Week Low$12.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-32.64%
ROA-9.97%
ROCE-6.77%
Gross Margin75.26%
Operating Margin-15.82%
Net Margin-20.73%
Debt/Equity2.87
Current Ratio3.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$154.0M$185.0M$170.0M$179.0M$277.0M
Operating Profit$-209.0M$-200.0M$-227.0M$-163.0M$-57.0M
Net Profit$-207.0M$-200.0M$-225.0M$-159.0M$-59.0M
EPS$-1.46$-1.00$-1.56$-1.08$-0.39
Op Margin-135.4%-108.0%-133.3%-90.8%-20.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$923.0M$857.0M$661.0M$539.0M$513.0M
Total Liabilities$319.0M$393.0M$353.0M$337.0M$288.0M
Cash$139.0M$90.0M$65.0M$48.0M$70.0M
Borrowings$112.0M$108.0M$99.0M$89.0M$281.0M

Latest News

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run Motley Fool · Jul 12, 2026 Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026 GlobeNewswire · Jul 9, 2026 Adaptive Biotechnologies Insider Sold Shares Worth $8,501,149, According to a Recent SEC Filing MT Newswires · Jul 8, 2026 Adaptive Biotechnologies Insider Sold Shares Worth $2,157,683, According to a Recent SEC Filing MT Newswires · Jul 7, 2026 Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial Exec Edge · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-193.0M$-184.0M$-156.0M$-95.0M$-46.0M
Investing Cash Flow$119.0M$-13.0M$119.0M$74.0M$35.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$16.0M$-49.0M$-25.0M$-17.0M$22.0M
Free Cash Flow$-254.0M$-200.0M$-167.0M$-99.0M$-49.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-1.42
EV / EBITDA-308.25
FCF Yield-0.51%
Quick Ratio4.68
Interest Coverage-3.26
Return 1Y89.26%
Return 3Y277.10%
Return 5Y-23.91%

Ownership

Insiders Held1.84%
Institutions Held96.60%
Institutions Float Held98.41%
Institutional HolderSharesReport Date
Viking Global Investors, L.P.29,993,7082026-03-31
Blackrock Inc.13,303,0252026-03-31
Vanguard Capital Management LLC6,094,1442026-03-31
Westfield Capital Management Co LP5,436,7182026-03-31
Vanguard Portfolio Management LLC4,491,4742026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation (ADPT) stock trades at $26.49 with a market capitalization of $4.24B. The stock is valued at a price-to-earnings (P/E) ratio of -71.77, price-to-book of 32.27, price-to-sales of 15.19. Over the past 52 weeks the stock has ranged between $12.00 and $30.30, and currently trades 12.6% below its 52-week high.

On profitability, Adaptive Biotechnologies Corporation generates a return on equity (ROE) of -32.64%, return on capital employed of -6.77%, an operating margin of -15.82%, a net profit margin of -20.73%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides